Expertise in
6
conditions

Philippe Corcia

CHU Bretonneau 2 Boulevard TONNELLE, 
Tours, FR 
Expertise in
6
conditions
CHU Bretonneau 2 Boulevard TONNELLE, 
Tours, FR 

Overview

Philippe Corcia practices practicing medicine in Tours, France.

Dr. Corcia is highly rated in 6 conditions, according to our data. His clinical expertise encompasses Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Primary Lateral Sclerosis, Hereditary Spastic Paraparesis, Chronic Inflammatory Demyelinating Polyneuropathy, and Gastrostomy.

He is actively involved in clinical research, co-authoring 269 peer reviewed articles and participating in 9 clinical trials.

Gender

Male

Locations

CHU Bretonneau 2 Boulevard TONNELLE, Tours, 37044, France
Other Locations
France
Strasbourg, France
Val-de-la-haye, France
Paris, France
Bron, France
Limoges, France
Lille, France
Francois, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Study of Predictive Factors of Progression of Motor Neurone Disease Prognosis and Endophenotype Biomarkers French Database Set up
Study of Predictive Factors of Progression of Motor Neurone Disease Prognosis and Endophenotype Biomarkers French Database Set up
Enrollment Status: Completed
Publish Date: May 05, 2026
Intervention Type: Other
New Therapeutic Strategy in ALS Based on Metabolic Status and Associated Metabolic Pathways.
New Therapeutic Strategy in ALS Based on Metabolic Status and Associated Metabolic Pathways.
Enrollment Status: Completed
Publish Date: December 30, 2025
Intervention Type: Other
Study Phase: Not Applicable
Metabolomics and Transcriptomics Approaches to Identify Muscular Biomarkers in Amyotrophic Lateral Sclerosis
Metabolomics and Transcriptomics Approaches to Identify Muscular Biomarkers in Amyotrophic Lateral Sclerosis
Enrollment Status: Completed
Publish Date: December 22, 2025
Intervention Type: Other
Study Phase: Not Applicable
Tear Fluid and Ocular Surface Metabolomics and Lipidomics in Lateral Amyotrophic Sclerosis: a Prospective Comparative Study
Tear Fluid and Ocular Surface Metabolomics and Lipidomics in Lateral Amyotrophic Sclerosis: a Prospective Comparative Study
Enrollment Status: Completed
Publish Date: December 22, 2025
Intervention Type: Other
Study Phase: Not Applicable
Efficacy and Safety of Low-dose IL-2 (Ld-IL-2) as a Treg Enhancer for Controlling Neuro-inflammation in Newly Diagnosed Amyotrophic Lateral Sclerosis (ALS) Patients: A Randomized, Double-blind, Placebo- Controlled, Phase-II Proof of Concept/ Proof of Mechanism Clinical Trial
Efficacy and Safety of Low-dose IL-2 (Ld-IL-2) as a Treg Enhancer for Controlling Neuro-inflammation in Newly Diagnosed Amyotrophic Lateral Sclerosis (ALS) Patients: A Randomized, Double-blind, Placebo- Controlled, Phase-II Proof of Concept/ Proof of Mechanism Clinical Trial
Enrollment Status: Completed
Publish Date: December 04, 2025
Intervention Type: Drug
Study Drugs: Riluzole, IL-2
Study Phase: Phase 2
Multicentric, Randomized, Double-blind Versus Placebo Study Evaluating the Efficacy of Treatment With Cholecalciferol (Vitamin D3) for Delaying the Diagnosis of Multiple Sclerosis (MS) After a Clinically Isolated Syndrome (CIS). Comparison of Conversion Rates After 2 Years.
Multicentric, Randomized, Double-blind Versus Placebo Study Evaluating the Efficacy of Treatment With Cholecalciferol (Vitamin D3) for Delaying the Diagnosis of Multiple Sclerosis (MS) After a Clinically Isolated Syndrome (CIS). Comparison of Conversion Rates After 2 Years.
Enrollment Status: Completed
Publish Date: January 12, 2024
Intervention Type: Biological, Drug, Other
Study Drugs: Vitamin D, Lumbar Puncture, Blood Sampling, Urine Samples
Study Phase: Phase 3
Safety and Efficacy of Tauroursodeoxycholic (TUDCA) as add-on Treatment in Patients Affected by Amyotrophic Lateral Sclerosis (ALS)
Safety and Efficacy of Tauroursodeoxycholic (TUDCA) as add-on Treatment in Patients Affected by Amyotrophic Lateral Sclerosis (ALS)
Enrollment Status: Unknown
Publish Date: July 10, 2023
Intervention Type: Drug
Study Drug: Tauroursodexycholic Acid
Study Phase: Phase 3
Evaluation of Metabolomic Analysis in Early Diagnosis of ALS
Evaluation of Metabolomic Analysis in Early Diagnosis of ALS
Enrollment Status: Completed
Publish Date: July 17, 2019
Intervention Type: Procedure
Study Phase: Not Applicable
Microglial Activation Role In ALS (MARIA)
Microglial Activation Role In ALS (MARIA)
Enrollment Status: Withdrawn
Publish Date: May 31, 2017
Intervention Type: Drug
Study Phase: Early Phase 1
View 8 Less Clinical Trials

269 Total Publications

Exploring the effect of red and near-infrared light on neurodegenerative disease: A focus on amyotrophic lateral sclerosis, Charcot's devastating disease of the motor system.
Exploring the effect of red and near-infrared light on neurodegenerative disease: A focus on amyotrophic lateral sclerosis, Charcot's devastating disease of the motor system.
Journal: International review of neurobiology
Published: August 18, 2026

Frequently Asked Questions about Philippe Corcia

Is Philippe Corcia a top-rated expert for Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease)?

MediFind is an objective health platform that identifies experts based on real-world data. Philippe Corcia is classified as an Elite expert for Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Philippe Corcia participate in research or clinical trials?

Yes. Philippe Corcia has published 269 articles and abstracts on conditions like Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease). You can view a list of Philippe Corcia's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Corcia's expertise for a condition
ConditionClose
    View All 42 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile